Date | Time | Source | Headline | Symbol | Company |
06/28/2024 | 7:00AM | GlobeNewswire Inc. | Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility | NASDAQ:ESPR | Esperion Therapeutics Inc |
06/18/2024 | 3:19PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
06/18/2024 | 3:09PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/28/2024 | 4:16PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/24/2024 | 4:18PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/24/2024 | 4:14PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/24/2024 | 4:13PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/23/2024 | 9:00AM | GlobeNewswire Inc. | Esperion to Participate in Upcoming June Investor Conferences | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/22/2024 | 8:00AM | GlobeNewswire Inc. | First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/20/2024 | 4:14PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/20/2024 | 6:00AM | GlobeNewswire Inc. | Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/17/2024 | 3:08PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/14/2024 | 8:00AM | GlobeNewswire Inc. | Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/10/2024 | 4:00PM | GlobeNewswire Inc. | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/08/2024 | 4:31PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/07/2024 | 8:50AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/07/2024 | 7:29AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/07/2024 | 6:00AM | GlobeNewswire Inc. | Esperion Reports First Quarter 2024 Financial Results | NASDAQ:ESPR | Esperion Therapeutics Inc |
04/29/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Participate in Upcoming May Investor Conferences | NASDAQ:ESPR | Esperion Therapeutics Inc |
04/23/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Report First Quarter 2024 Financial Results on May 7 | NASDAQ:ESPR | Esperion Therapeutics Inc |
04/07/2024 | 2:45PM | GlobeNewswire Inc. | Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity | NASDAQ:ESPR | Esperion Therapeutics Inc |
04/01/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 | NASDAQ:ESPR | Esperion Therapeutics Inc |
03/26/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:ESPR | Esperion Therapeutics Inc |
03/25/2024 | 4:00PM | GlobeNewswire Inc. | Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 | NASDAQ:ESPR | Esperion Therapeutics Inc |
03/22/2024 | 6:26PM | Business Wire | U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use | NASDAQ:ESPR | Esperion Therapeutics Inc |
03/22/2024 | 3:10PM | GlobeNewswire Inc. | U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use | NASDAQ:ESPR | Esperion Therapeutics Inc |
03/22/2024 | 11:04AM | GlobeNewswire Inc. | CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events | NASDAQ:ESPR | Esperion Therapeutics Inc |
02/27/2024 | 9:19AM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ESPR | Esperion Therapeutics Inc |
02/27/2024 | 7:23AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
02/27/2024 | 6:00AM | GlobeNewswire Inc. | Esperion Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:ESPR | Esperion Therapeutics Inc |